Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;37(2-3):335-345.
doi: 10.1007/s10555-018-9751-z.

Evaluation of Oncogenic Cysteinyl Leukotriene Receptor 2 as a Therapeutic Target for Uveal Melanoma

Affiliations
Review

Evaluation of Oncogenic Cysteinyl Leukotriene Receptor 2 as a Therapeutic Target for Uveal Melanoma

K Slater et al. Cancer Metastasis Rev. .

Abstract

Uveal melanoma is a rare, but deadly, form of eye cancer that arises from melanocytes within the uveal tract. Although advances have emerged in treatment of the primary tumour, patients are still faced with vision loss, eye enucleation and lethal metastatic spread of the disease. Approximately 50% of uveal melanoma patients develop metastases, which occur most frequently in the liver. Metastatic patients encounter an extremely poor prognosis; as few as 8% survive beyond 2 years. Understanding of the genetic underpinnings of this fatal disease evolved in recent years with the identification of new oncogenic mutations that drive uveal melanoma pathogenesis. Despite this progress, the lack of successful therapies or a proven standard-of-care for uveal melanoma highlights the need for new targeted therapies. This review focuses on the recently identified CYSLTR2 oncogenic mutation in uveal melanoma. Here, we evaluate the current status of uveal melanoma and investigate how to better understand the role of this CYSLTR2 mutation in the disease and implications for patients harbouring this mutation.

Keywords: Cysteinyl leukotriene receptor 2; Cysteinyl leukotriene signalling; Patient-derived xenograft models; Uveal melanoma.

Similar articles

See all similar articles

Cited by 2 articles

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources

Feedback